Bill > S1428

This bill, the Preserve Access to Affordable Generics and Biosimilars Act, aims to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar and interchangeable biological products. The bill seeks to enhance competition in the pharmaceutical market and support the purpose of antitrust law by prohibiting these anticompetitive practices that can harm consumers. The bill includes provisions to define key terms, establish a presumption of anticompetitive effects for certain agreements, outline enforcement mechanisms and penalties, and require certification and notification of relevant agreements.

Justice

https://www.congress.gov/bill/117th-congress/senate-bill/1428/all-info